STAAR Surgical Co（STAA）股票分析STAASTAAR Surgical Co

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

STAAR Surgical Co is currently a hold. The stock is priced at $22.61, which is below the recent analyst target of $31, indicating potential upside. However, the forward P/E ratio is high at 62.5, suggesting that the stock may be overvalued relative to its earnings. Additionally, while the stock has seen a positive 5-day change of +6.30%, it has a significant risk due to an ongoing investigation into fiduciary breaches, which could negatively impact investor confidence.

5 analysts cover STAA: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 30.75.